--- title: "United-Guardian | 10-Q: FY2026 Q1 Revenue: USD 2.872 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/286104933.md" datetime: "2026-05-12T13:03:02.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286104933.md) - [en](https://longbridge.com/en/news/286104933.md) - [zh-HK](https://longbridge.com/zh-HK/news/286104933.md) --- # United-Guardian | 10-Q: FY2026 Q1 Revenue: USD 2.872 M Revenue: As of FY2026 Q1, the actual value is USD 2.872 M. EPS: As of FY2026 Q1, the actual value is USD 0.18. EBIT: As of FY2026 Q1, the actual value is USD 572.64 K. #### Segment Revenue Net sales for United-Guardian, Inc. for the first quarter of 2026 increased by $391,095 (approximately 16%) to $2,872,222, compared to $2,481,127 in the first quarter of 2025. Net sales of pharmaceutical products increased by approximately 24%, from $1,168,458 in Q1 2025 to $1,445,324 in Q1 2026. Gross sales for these products increased by approximately 24%, reaching $1,694,182 in Q1 2026 from $1,367,979 in Q1 2025. Specifically, Renacidin gross sales grew by approximately 24% to $1,522,326, and Clorpactin gross sales increased by approximately 27% to $171,856 in Q1 2026. Pharmaceutical-related sales allowances rose by $49,337 (approximately 25%) primarily due to higher VA chargebacks and distribution fees. Sales of cosmetic ingredients increased by $144,909 (approximately 21%) in Q1 2026 compared to Q1 2025. This was driven by a $203,099 (approximately 45%) increase in purchases by ASI, a U.S.-based distributor, which resumed regular purchases after an overstock situation in 2025. This increase was partially offset by a $54,963 (approximately 23%) decrease in sales to three other distributors and a $3,227 decrease to two direct customers in the United States. Sales of medical lubricants decreased by $30,680 (approximately 5%) in Q1 2026 compared to Q1 2025, attributed to customer ordering patterns. Geographically, sales to customers outside of the United States constituted approximately 22% of total sales in Q1 2026, a decrease from approximately 29% in Q1 2025. United States sales were $2,236,248 in Q1 2026, up from $1,757,267 in Q1 2025, while sales to other countries were $635,974, down from $723,860 in Q1 2025. Approximately 71% of ASI’s sales of United-Guardian, Inc.’s products were to customers in other countries in Q1 2026 (with China representing about 36%), compared to 69% in Q1 2025 (with China representing about 41%). #### Operational Metrics Cost of sales as a percentage of net sales increased to 50% in Q1 2026, up from 45% in Q1 2025, due to a larger proportion of pharmaceutical product sales which have higher tolling unit costs. Operating expenses increased by $34,228 (approximately 5%) in Q1 2026, mainly due to increases in sales & marketing and payroll expenses. Research and development expenses saw a slight increase of $627 (less than 1%) in Q1 2026. Investment income decreased by $14,873 (approximately 18%) in Q1 2026, primarily due to lower interest rates on U.S. Treasury Bills. Net gain on marketable securities increased from $12,350 in Q1 2025 to $17,742 in Q1 2026, driven by a gain from the sale of equity mutual funds. United-Guardian, Inc. recognized $303,133 in settlement income in Q1 2026 related to an agreement with its contract manufacturer for Renacidin, with an additional $35,000 in product expected in Q2 2026. Net income for Q1 2026 was $818,902, up from $560,895 in Q1 2025. Working capital decreased by $187,320 to $10,344,756 at March 31, 2026, from $10,532,076 at December 31, 2025, primarily due to a decrease in cash and cash equivalents. The current ratio increased to 8.1 to 1 at March 31, 2026, from 7.3 to 1 at December 31, 2025, primarily due to a decrease in accounts payable. #### Cash Flow Net cash provided by operating activities increased to $604,536 in Q1 2026 from $322,080 in Q1 2025, primarily due to an increase in net income. Cash provided by investing activities decreased to $30,113 in Q1 2026 from $679,370 in Q1 2025, mainly due to increased purchases of marketable securities. Net cash used in financing activities decreased to -$1,149,892 in Q1 2026 from -$1,607,893 in Q1 2025, primarily due to the payment of lower dividends ($0.25 per share in Q1 2026 vs $0.35 per share in Q1 2025). #### Future Outlook and Strategy United-Guardian, Inc. has entered a new distribution agreement with Brenntag Specialties for its Natrajel® line of sexual wellness ingredients in the United States, Canada, and Mexico, and for Lubrajel® and Natrajel products in France, anticipating higher compound annual growth in this segment. For pharmaceutical products, the company’s insurance payer outreach program for Renacidin secured formulary inclusion with two major Pharmacy Benefit Managers starting in 2026, with further outreach planned to increase awareness among healthcare professionals. In cosmetic ingredients, United-Guardian, Inc. plans to strengthen core capabilities and invest in new product development, particularly in naturally-derived products, to address global competition while maintaining competitive pricing and high-quality offerings. United-Guardian, Inc. expects its effective income tax rate to remain at 21% for the current fiscal year and believes that working capital will be sufficient for operating requirements for at least the next twelve months. The company plans to continue using cash for dividend payments, purchasing marketable securities, and pursuing growth opportunities that benefit the Company and its shareholders. ### Related Stocks - [UG.US](https://longbridge.com/en/quote/UG.US.md) ## Related News & Research - [Yext to Announce First Quarter Fiscal Year 2027 Financial Results on June 2, 2026 | YEXT Stock News](https://longbridge.com/en/news/286970613.md) - [Hafnia’s Q1 2026 Financial Results Presentation to Be Held on 27 May 2026 | HAFN Stock News](https://longbridge.com/en/news/287014236.md) - [LOWE'S REPORTS FIRST QUARTER 2026 SALES AND EARNINGS RESULTS | LOW Stock News](https://longbridge.com/en/news/287043063.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [Prairie Operating Co. Announces First Quarter 2026 Results and Reaffirms 2026 Guidance | PROP Stock News](https://longbridge.com/en/news/286463109.md)